Review



gene exp gapdh mm99999915 g1  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Thermo Fisher gene exp gapdh mm99999915 g1
    Meis1 Increases Syk Protein Levels in Hoxa9-Driven Leukemia (A) Kaplan-Meier survival curves of mice transplanted with either H- or H/M-transformed myeloid progenitor cells (n = 11). The p value is from a Mantel-Cox test. (B) Volcano plot relating q values for differential protein expression to average normalized SILAC ratios from six biological replicates. Blue (higher expression in H cells) and orange (higher expression in H/M cells) dots indicate significantly regulated proteins (q < 0.01). (C) Heatmap of SILAC ratios for significantly differentially expressed proteins in H and H/M cells across the six biological replicates. (D) Syk protein expression in H and H/M cells by immunoblotting. Actin was used as loading control for relative protein quantification. (E) Relative Syk mRNA expression as measured by qPCR, normalized to <t>GAPDH</t> expression (mean ± SD, n = 3); ns, not significant (two-sided unpaired t test). (F and G) Immunohistochemical staining of HOXA9, MEIS1, and SYK in bone marrow biopsies from patients with AML. SYK expression levels were analyzed in 21 AML cases with high HOXA9 expression (F) and 28 cases with high HOXA9/MEIS1 expression (G). Proportions of SYK expression levels as determined by two independent pathologists using a three-stage staining score are shown. See also <xref ref-type=Figure S1 , , and . " width="250" height="auto" />
    Gene Exp Gapdh Mm99999915 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microrna+microarray+gene+expression+experiments/Gene+Exp%2E+Gapdh%2C+Mm99999915_g1/pmc05389883-77-13-5
    Average 99 stars, based on 1 article reviews
    gene exp gapdh mm99999915 g1 - by Bioz Stars, 2026-11
    99/100 stars

    Images

    1) Product Images from "Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia"

    Article Title: Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia

    Journal: Cancer Cell

    doi: 10.1016/j.ccell.2017.03.001

    Meis1 Increases Syk Protein Levels in Hoxa9-Driven Leukemia (A) Kaplan-Meier survival curves of mice transplanted with either H- or H/M-transformed myeloid progenitor cells (n = 11). The p value is from a Mantel-Cox test. (B) Volcano plot relating q values for differential protein expression to average normalized SILAC ratios from six biological replicates. Blue (higher expression in H cells) and orange (higher expression in H/M cells) dots indicate significantly regulated proteins (q < 0.01). (C) Heatmap of SILAC ratios for significantly differentially expressed proteins in H and H/M cells across the six biological replicates. (D) Syk protein expression in H and H/M cells by immunoblotting. Actin was used as loading control for relative protein quantification. (E) Relative Syk mRNA expression as measured by qPCR, normalized to GAPDH expression (mean ± SD, n = 3); ns, not significant (two-sided unpaired t test). (F and G) Immunohistochemical staining of HOXA9, MEIS1, and SYK in bone marrow biopsies from patients with AML. SYK expression levels were analyzed in 21 AML cases with high HOXA9 expression (F) and 28 cases with high HOXA9/MEIS1 expression (G). Proportions of SYK expression levels as determined by two independent pathologists using a three-stage staining score are shown. See also <xref ref-type=Figure S1 , , and . " title="... mRNA expression as measured by qPCR, normalized to GAPDH expression (mean ± SD, n = 3); ns, ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Meis1 Increases Syk Protein Levels in Hoxa9-Driven Leukemia (A) Kaplan-Meier survival curves of mice transplanted with either H- or H/M-transformed myeloid progenitor cells (n = 11). The p value is from a Mantel-Cox test. (B) Volcano plot relating q values for differential protein expression to average normalized SILAC ratios from six biological replicates. Blue (higher expression in H cells) and orange (higher expression in H/M cells) dots indicate significantly regulated proteins (q < 0.01). (C) Heatmap of SILAC ratios for significantly differentially expressed proteins in H and H/M cells across the six biological replicates. (D) Syk protein expression in H and H/M cells by immunoblotting. Actin was used as loading control for relative protein quantification. (E) Relative Syk mRNA expression as measured by qPCR, normalized to GAPDH expression (mean ± SD, n = 3); ns, not significant (two-sided unpaired t test). (F and G) Immunohistochemical staining of HOXA9, MEIS1, and SYK in bone marrow biopsies from patients with AML. SYK expression levels were analyzed in 21 AML cases with high HOXA9 expression (F) and 28 cases with high HOXA9/MEIS1 expression (G). Proportions of SYK expression levels as determined by two independent pathologists using a three-stage staining score are shown. See also Figure S1 , , and .

    Techniques Used: Transformation Assay, Expressing, Multiplex sample analysis, Western Blot, Control, Immunohistochemical staining, Staining

    Syk Is a Direct Target of miR-146a (A) Schematic workflow of the miRNA expression analysis in H- and H/M-transformed myeloid progenitors. (B) Volcano plot relating q values for differential miRNA expression between H and H/M cells to average miRNA expression fold-changes from three biological replicates. Blue (higher expression in H cells) and orange (higher expression in H/M cells) dots indicate significantly regulated miRNAs (q < 0.01). (C and D) Relative mmu-miR-146a expression (C) and pri-miR-146a expression (D) in H/M versus H cells, measured by qPCR and normalized to sno202 and GAPDH expression, respectively (mean ± SD, n = 3). The p values are from a two-sided unpaired t test. (E) Luciferase assay validating binding of miR-146a to the predicted target sites within the 3′ UTR of Syk (mean ± SD, n = 4); WT, predicted miR-146a target sequence; MUT, mutated version thereof. The p values are from a two-sided unpaired t test. ns, not significant. (F) Luciferase assay validating binding of miR-146a to the full-length Syk 3′ UTR (mean ± SD, n = 4). The p value is from a two-sided unpaired t test. (G) Left, secondary structure of mmu-miR-146 as predicted by RNAfold ( <xref ref-type=Lorenz et al., 2011 ). The CRISPR/Cas9 cleavage site is indicated. Right, relative expression of miR-146a, measured by qPCR and normalized to sno202 expression, in H cells transduced with either a lentiviral non-specific (nsp) control CRISPR or a CRISPR targeting miR-146 (ΔmiR-146) (mean ± SD, n = 3). The p value is from a two-sided unpaired t test. (H) Corresponding Syk protein expression by immunoblotting. Actin was used as loading control for relative protein quantification. (I) Cell-proliferation curves for H cells transduced with either a lentiviral non-specific (nsp) control CRISPR or a CRISPR targeting miR-146 (ΔmiR-146) (mean ± SD, n = 3). (J) Kaplan-Meier survival curves of mice transplanted with H or H/M cells transduced with a lentiviral non-specific (nsp) control CRISPR, or with H cells transduced with a CRISPR targeting miR-146 (ΔmiR-146) (n = 7). The p value is from a Mantel-Cox test. See also Figure S3 . " title="... measured by qPCR and normalized to sno202 and GAPDH expression, respectively (mean ± SD, n = 3). ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Syk Is a Direct Target of miR-146a (A) Schematic workflow of the miRNA expression analysis in H- and H/M-transformed myeloid progenitors. (B) Volcano plot relating q values for differential miRNA expression between H and H/M cells to average miRNA expression fold-changes from three biological replicates. Blue (higher expression in H cells) and orange (higher expression in H/M cells) dots indicate significantly regulated miRNAs (q < 0.01). (C and D) Relative mmu-miR-146a expression (C) and pri-miR-146a expression (D) in H/M versus H cells, measured by qPCR and normalized to sno202 and GAPDH expression, respectively (mean ± SD, n = 3). The p values are from a two-sided unpaired t test. (E) Luciferase assay validating binding of miR-146a to the predicted target sites within the 3′ UTR of Syk (mean ± SD, n = 4); WT, predicted miR-146a target sequence; MUT, mutated version thereof. The p values are from a two-sided unpaired t test. ns, not significant. (F) Luciferase assay validating binding of miR-146a to the full-length Syk 3′ UTR (mean ± SD, n = 4). The p value is from a two-sided unpaired t test. (G) Left, secondary structure of mmu-miR-146 as predicted by RNAfold ( Lorenz et al., 2011 ). The CRISPR/Cas9 cleavage site is indicated. Right, relative expression of miR-146a, measured by qPCR and normalized to sno202 expression, in H cells transduced with either a lentiviral non-specific (nsp) control CRISPR or a CRISPR targeting miR-146 (ΔmiR-146) (mean ± SD, n = 3). The p value is from a two-sided unpaired t test. (H) Corresponding Syk protein expression by immunoblotting. Actin was used as loading control for relative protein quantification. (I) Cell-proliferation curves for H cells transduced with either a lentiviral non-specific (nsp) control CRISPR or a CRISPR targeting miR-146 (ΔmiR-146) (mean ± SD, n = 3). (J) Kaplan-Meier survival curves of mice transplanted with H or H/M cells transduced with a lentiviral non-specific (nsp) control CRISPR, or with H cells transduced with a CRISPR targeting miR-146 (ΔmiR-146) (n = 7). The p value is from a Mantel-Cox test. See also Figure S3 .

    Techniques Used: Expressing, Transformation Assay, Luciferase, Binding Assay, Sequencing, CRISPR, Transduction, Control, Western Blot

    Meis1 Downregulates miR-146a through PU.1 (A) Fold enrichment of PU.1 binding over IgG control as measured by ChIP-qPCR in H and H/M cells (mean ± SD, n = 3). The miR-146a −10 kb region spans the transcription start site of the miR-146a host gene; ns, not significant. (B) PU.1 protein expression in H and H/M cells by immunoblotting. Histone H3 was used as loading control for relative protein quantification. (C) Relative PU.1 mRNA expression in H versus H/M cells measured by qPCR and normalized to GAPDH expression (mean ± SD, n = 3). (D and E) Immunohistochemical staining of PU.1 in bone marrow biopsies from patients with AML. PU.1 expression levels were analyzed in 21 AML cases with high HOXA9 expression (D) and 28 cases with high HOXA9/MEIS1 expression (E). Proportions of PU.1 expression levels as determined by two independent pathologists using a three-stage staining score are shown. (F) PU.1 and SYK protein expression by immunoblotting in H cells transfected with either a control shRNA (nsp) or an shRNA targeting PU.1 (KD). Tubulin was used as loading control for relative protein quantification. (G) mmu-miR-146a and pri-miR-146a expression as measured by qPCR after PU.1 knockdown (KD) relative to control shRNA (nsp) (mean ± SD, n = 4). The p values are from a two-sided unpaired t test. See also <xref ref-type=Figure S4 and . " title="... H/M cells measured by qPCR and normalized to GAPDH expression (mean ± SD, n = 3). (D ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Meis1 Downregulates miR-146a through PU.1 (A) Fold enrichment of PU.1 binding over IgG control as measured by ChIP-qPCR in H and H/M cells (mean ± SD, n = 3). The miR-146a −10 kb region spans the transcription start site of the miR-146a host gene; ns, not significant. (B) PU.1 protein expression in H and H/M cells by immunoblotting. Histone H3 was used as loading control for relative protein quantification. (C) Relative PU.1 mRNA expression in H versus H/M cells measured by qPCR and normalized to GAPDH expression (mean ± SD, n = 3). (D and E) Immunohistochemical staining of PU.1 in bone marrow biopsies from patients with AML. PU.1 expression levels were analyzed in 21 AML cases with high HOXA9 expression (D) and 28 cases with high HOXA9/MEIS1 expression (E). Proportions of PU.1 expression levels as determined by two independent pathologists using a three-stage staining score are shown. (F) PU.1 and SYK protein expression by immunoblotting in H cells transfected with either a control shRNA (nsp) or an shRNA targeting PU.1 (KD). Tubulin was used as loading control for relative protein quantification. (G) mmu-miR-146a and pri-miR-146a expression as measured by qPCR after PU.1 knockdown (KD) relative to control shRNA (nsp) (mean ± SD, n = 4). The p values are from a two-sided unpaired t test. See also Figure S4 and .

    Techniques Used: Binding Assay, Control, ChIP-qPCR, Expressing, Western Blot, Immunohistochemical staining, Staining, Transfection, shRNA, Knockdown

    Meis1 Sensitizes Hoxa9-Driven Leukemia to Syk Inhibition (A) Syk protein expression in H/M cells transfected with either a control shRNA (GL2) or two shRNAs targeting Syk. Actin was used as loading control for relative protein quantification. (B) Percentage of BFP-positive shRNA-expressing cells relative to BFP-negative shRNA-negative cells at the times indicated (mean ± SD, normalized to day 0, n = 3). (C) Same as (A), before and after 5 days of doxycycline (dox) treatment in vivo. (D) Kaplan-Meier survival curves of mice transplanted with H/M cells and treated with doxycycline for 43 days to express non-specific control and Syk-specific shRNA (n = 8). The p value is from a Mantel-Cox test. (E) Percentage of YFP-positive cells from peripheral blood of mice transplanted with H (left) or H/M (right) cells after treating for 7 days with R788 or placebo. Measurements were taken at the indicated time points. The black line connects median values. (F) Kaplan-Meier survival curves of mice transplanted with either H or H/M cells and treated for 20 days with R788 or placebo (n = 11). The p value is from a Mantel-Cox test. (G) Relative HOXA9 and MEIS1 mRNA expression in MV4-11 and KG1 cell lines, and in patient-derived AML cells as measured by qPCR, normalized to GAPDH expression (mean ± SD, n = 3). (H) (p)SYK expression in the patient-derived AML cells in (G). Actin was used as loading control for relative protein quantification. avg, average. (I) Half maximal inhibitory concentration (IC 50 ) for R406 (left) and PRT062607 (right) in patient-derived AML cells as determined by an Annexin V/7-AAD apoptosis assay. Cells were treated for 24 hr and DMSO was used as a control (n = 3). Representative dose-response curves for AML no. 1 (HOXA9 high, MEIS1 low) and AML no. 5 (HOXA9 high, MEIS1 high) are shown at the top. Ticks correspond to estimated IC 50 values. (J) Relative viability of CD34 + bone marrow cells from healthy donors. Cells were treated with either R406 or PRT062607. Blue lines indicate the IC 50 for both SYK inhibitors in H cells. (K) Kaplan-Meier survival curves of NSG mice transplanted with patient-derived AML cells indicated in (G) and treated for 14 days with R788 or vehicle (n = 6 for AML no. 1 and 5; n = 5 for AML no. 2 and 6). The p values are from a Mantel-Cox test. See also <xref ref-type=Figure S6 . " title="... AML cells as measured by qPCR, normalized to GAPDH expression (mean ± SD, n = 3). (H) ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Meis1 Sensitizes Hoxa9-Driven Leukemia to Syk Inhibition (A) Syk protein expression in H/M cells transfected with either a control shRNA (GL2) or two shRNAs targeting Syk. Actin was used as loading control for relative protein quantification. (B) Percentage of BFP-positive shRNA-expressing cells relative to BFP-negative shRNA-negative cells at the times indicated (mean ± SD, normalized to day 0, n = 3). (C) Same as (A), before and after 5 days of doxycycline (dox) treatment in vivo. (D) Kaplan-Meier survival curves of mice transplanted with H/M cells and treated with doxycycline for 43 days to express non-specific control and Syk-specific shRNA (n = 8). The p value is from a Mantel-Cox test. (E) Percentage of YFP-positive cells from peripheral blood of mice transplanted with H (left) or H/M (right) cells after treating for 7 days with R788 or placebo. Measurements were taken at the indicated time points. The black line connects median values. (F) Kaplan-Meier survival curves of mice transplanted with either H or H/M cells and treated for 20 days with R788 or placebo (n = 11). The p value is from a Mantel-Cox test. (G) Relative HOXA9 and MEIS1 mRNA expression in MV4-11 and KG1 cell lines, and in patient-derived AML cells as measured by qPCR, normalized to GAPDH expression (mean ± SD, n = 3). (H) (p)SYK expression in the patient-derived AML cells in (G). Actin was used as loading control for relative protein quantification. avg, average. (I) Half maximal inhibitory concentration (IC 50 ) for R406 (left) and PRT062607 (right) in patient-derived AML cells as determined by an Annexin V/7-AAD apoptosis assay. Cells were treated for 24 hr and DMSO was used as a control (n = 3). Representative dose-response curves for AML no. 1 (HOXA9 high, MEIS1 low) and AML no. 5 (HOXA9 high, MEIS1 high) are shown at the top. Ticks correspond to estimated IC 50 values. (J) Relative viability of CD34 + bone marrow cells from healthy donors. Cells were treated with either R406 or PRT062607. Blue lines indicate the IC 50 for both SYK inhibitors in H cells. (K) Kaplan-Meier survival curves of NSG mice transplanted with patient-derived AML cells indicated in (G) and treated for 14 days with R788 or vehicle (n = 6 for AML no. 1 and 5; n = 5 for AML no. 2 and 6). The p values are from a Mantel-Cox test. See also Figure S6 .

    Techniques Used: Inhibition, Expressing, Transfection, Control, shRNA, In Vivo, Derivative Assay, Concentration Assay, Apoptosis Assay


    Figure Legend Snippet:

    Techniques Used: Recombinant, Blocking Assay, Lysis, SYBR Green Assay, Reporter Assay, Extraction, Bicinchoninic Acid Protein Assay, cDNA Synthesis, Reverse Transcription, TaqMan microRNA Assay, Mass Spectrometry, Microarray, Gene Expression, Retroviral, Negative Control, Plasmid Preparation, Software, Multiplex sample analysis

    Related Articles

    other:


    Article Title: Safety, efficacy, and distal nerve Schwann cell biodistribution in mice and NHPs to support translation of AAV9 RNAi therapy for CMT1A
    Article Snippet: Rpl13 (Mm02526700_g1; Applied Biosystems) served as the reference gene.

    Article Title: Hemoglobin inhibits fibroblast-to-cardiomyocyte reprogramming via TLR2/TLR4-dependent chromatin compaction
    Article Snippet: For qPCR, 4 μL of the synthesized cDNA was used along with FAM-tagged gene-specific primers and TaqMan Gene Expression Master Mix, both from Applied Biosystems, Waltham, MA, USA.

    Article Title: Multi-omics reveals molecular signatures of moderate intensity exercise and identifies candidate exercise mimetics in mice
    Article Snippet: mRNA expression was analyzed by quantitative real-time PCR using the StepOne real-time PCR system (Applied Biosystems, Foster City, CA, USA) and the Taqman Gene Expression Assay (Applied Biosystems).

    Article Title: Esophagus extracellular matrix with microenvironmental complexity for esophageal organoids
    Article Snippet: The liver organoid culture medium consisted of basal medium supplemented with 10 % (v/v) R-spondin1-conditioned medium, 1 × B27, 1 × N2, 1 mM N-acetyl-L-cysteine, 10 mM nicotinamide, 10 nM [Leu 15 ]-Gastrin I, 50 ng mL −1 mouse EGF, 100 ng mL −1 human fibroblast growth factor 10 (FGF10; Peprotech), and 50 ng mL −1 human hepatocyte growth factor (HGF; Peprotech).

    TaqMan Assay:

    Article Title: Microglial Histaminergic Signaling Promotes Interleukin-10 Production and Ameliorates Motor Dysfunction in Parkinson's Disease
    Article Snippet: Reverse transcription and cDNA pre-amplification were performed on thermal cycler (Applied Biosystems, Foster City, CA) according to the kit protocol. .. The TaqMan assay probes were designed by and purchased from Life Technologies as follows: Mm00456104_m1 for HDC, Mm01288386_m1 for IL-10, Mm01195085_m1 for CC3, and Mm99999915_g1 for gapdh. .. The TaqMan assay probes were designed by and purchased from Life Technologies as follows: Mm00456104_m1 for HDC, Mm01288386_m1 for IL-10, Mm01195085_m1 for CC3, and Mm99999915_g1 for gapdh.

    Knockdown:

    Article Title: Development of CAR Exosomes Targeting FAP for the Treatment of Intrauterine Adhesion
    Article Snippet: .. The knockdown efficiency in T cells following shRNA transduction was determined by real‐time quantitative PCR with TaqMan gene expression assays (Applied Biosystems) for Tet2 (assay Mm00524395_m1), and Gapdh (assay Mm99999915_g1) served as a loading and normalization control. ..

    shRNA:

    Article Title: Development of CAR Exosomes Targeting FAP for the Treatment of Intrauterine Adhesion
    Article Snippet: .. The knockdown efficiency in T cells following shRNA transduction was determined by real‐time quantitative PCR with TaqMan gene expression assays (Applied Biosystems) for Tet2 (assay Mm00524395_m1), and Gapdh (assay Mm99999915_g1) served as a loading and normalization control. ..

    Transduction:

    Article Title: Development of CAR Exosomes Targeting FAP for the Treatment of Intrauterine Adhesion
    Article Snippet: .. The knockdown efficiency in T cells following shRNA transduction was determined by real‐time quantitative PCR with TaqMan gene expression assays (Applied Biosystems) for Tet2 (assay Mm00524395_m1), and Gapdh (assay Mm99999915_g1) served as a loading and normalization control. ..

    Real-time Polymerase Chain Reaction:

    Article Title: Development of CAR Exosomes Targeting FAP for the Treatment of Intrauterine Adhesion
    Article Snippet: .. The knockdown efficiency in T cells following shRNA transduction was determined by real‐time quantitative PCR with TaqMan gene expression assays (Applied Biosystems) for Tet2 (assay Mm00524395_m1), and Gapdh (assay Mm99999915_g1) served as a loading and normalization control. ..

    Gene Expression:

    Article Title: Development of CAR Exosomes Targeting FAP for the Treatment of Intrauterine Adhesion
    Article Snippet: .. The knockdown efficiency in T cells following shRNA transduction was determined by real‐time quantitative PCR with TaqMan gene expression assays (Applied Biosystems) for Tet2 (assay Mm00524395_m1), and Gapdh (assay Mm99999915_g1) served as a loading and normalization control. ..

    Control:

    Article Title: Development of CAR Exosomes Targeting FAP for the Treatment of Intrauterine Adhesion
    Article Snippet: .. The knockdown efficiency in T cells following shRNA transduction was determined by real‐time quantitative PCR with TaqMan gene expression assays (Applied Biosystems) for Tet2 (assay Mm00524395_m1), and Gapdh (assay Mm99999915_g1) served as a loading and normalization control. ..



    Similar Products

    90
    Shanghai Biotechnology Co Ltd microrna microarray gene expression experiments
    ZEB1-AS1 sponges miR-141-3p in CRC cells. ( A ) Nuclear and cytoplasmic fractionation was analyzed for ZEB1-AS1 expression in SW480 and LOVO. ( B ) The <t>microRNA</t> array analysis in normal and tumor tissues. ( C ) The potential binding sites between ZEB1-AS1 and miR-141-3p. ( D ) The expressions of miR-141-3p in CRC tissues were detected by RT-qPCR. ( E ) Luciferase reporter assay showed ZEB1-AS1-wt activity was impaired by miR-141-3p. ( F ) The expression of miR-141-3p in SW480 and LOVO was upregulated after ZEB1-AS1 expression was downregulated identified by RT-qPCR. ( G ) The expression of miR-141-3p was negatively correlated with ZEB1-AS1 expression in CRC tissues. * P < 0.05.
    Microrna Microarray Gene Expression Experiments, supplied by Shanghai Biotechnology Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/microrna+microarray+gene+expression+experiments/human+mirna+microarray/pmc07359398-65-6-0
    Average 90 stars, based on 1 article reviews
    microrna microarray gene expression experiments - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    ZEB1-AS1 sponges miR-141-3p in CRC cells. ( A ) Nuclear and cytoplasmic fractionation was analyzed for ZEB1-AS1 expression in SW480 and LOVO. ( B ) The microRNA array analysis in normal and tumor tissues. ( C ) The potential binding sites between ZEB1-AS1 and miR-141-3p. ( D ) The expressions of miR-141-3p in CRC tissues were detected by RT-qPCR. ( E ) Luciferase reporter assay showed ZEB1-AS1-wt activity was impaired by miR-141-3p. ( F ) The expression of miR-141-3p in SW480 and LOVO was upregulated after ZEB1-AS1 expression was downregulated identified by RT-qPCR. ( G ) The expression of miR-141-3p was negatively correlated with ZEB1-AS1 expression in CRC tissues. * P < 0.05.

    Journal: International Journal of Medical Sciences

    Article Title: Long noncoding RNA ZEB1-AS1 acts as a Sponge of miR-141-3p to Inhibit Cell Proliferation in Colorectal Cancer

    doi: 10.7150/ijms.46698

    Figure Lengend Snippet: ZEB1-AS1 sponges miR-141-3p in CRC cells. ( A ) Nuclear and cytoplasmic fractionation was analyzed for ZEB1-AS1 expression in SW480 and LOVO. ( B ) The microRNA array analysis in normal and tumor tissues. ( C ) The potential binding sites between ZEB1-AS1 and miR-141-3p. ( D ) The expressions of miR-141-3p in CRC tissues were detected by RT-qPCR. ( E ) Luciferase reporter assay showed ZEB1-AS1-wt activity was impaired by miR-141-3p. ( F ) The expression of miR-141-3p in SW480 and LOVO was upregulated after ZEB1-AS1 expression was downregulated identified by RT-qPCR. ( G ) The expression of miR-141-3p was negatively correlated with ZEB1-AS1 expression in CRC tissues. * P < 0.05.

    Article Snippet: Shanghai Biotechnology Co., Ltd conducted the microRNA microarray gene expression experiments and data analysis.

    Techniques: Fractionation, Expressing, Binding Assay, Quantitative RT-PCR, Luciferase, Reporter Assay, Activity Assay